Tech Company Financing Transactions

Amber Bio Funding Round

Andreessen Horowitz, Playground Global and Eli Lilly and Company participated in a $26 million Seed funding round for Amber Bio. The funding round was announced on 8/3/2023.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

953 Indiana St
San Francisco, CA 94107
USA

Phone

Undisclosed

Website

www.amber.bio

Email Address

Undisclosed

Overview

Amber Bio is a biotechnology company pioneering new gene editing modalities using multi-kilobase edits to reach previously undruggable patient populations. The current paradigm in genetic medicine relies on developing independent therapies for each separate mutation in the patient population. Founded by pioneers in the CRISPR field from leading institutions for gene editing research, the company is developing a first-of-its-kind RNA writing platform capable of editing thousands of diverse mutations across patients with a single product.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Jacob Borrajo

        

Chief Technical Officer

Basem Al-Shayeb

        

Browse more venture capital transactions:

Prev: 8/3/2023: Newlight Technologies venture capital transaction
Next: 8/3/2023: Hologate venture capital transaction

Share this article

Where The Data Comes From

We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary